stockrowNovavax, Inc.
NVAX Healthcare Biotechnology
Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.
- Revenue
- −3.05%
- EPS
- +84.8%
- Free cash flow
- −189.1%
- Total debt
- +31.5%
Quarter to September 2026, against a year earlier
Follow NVAX
Alert me
Novavax, Inc. (NVAX) EV/Sales
As of 6 November 2026, Novavax, Inc. (NVAX) trades at a EV/Sales of 3.3×. Over the past ten years it has ranged from −0.4× (March 2023) to 210× (June 2020); the current reading is higher than 38% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.5× | (30.33%) |
| FY2024 | 0.8× | 174.80% |
| FY2023 | 0.3× | — |
| FY2022 | −0.2× | — |
| FY2021 | 8.2× | (34.44%) |
| FY2020 | 12.6× | (29.96%) |
| FY2019 | 17.9× | (31.40%) |
| FY2018 | 26.1× | 59.01% |
| FY2017 | 16.4× | (36.00%) |
| FY2016 | 25.7× | (51.86%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.3× | 21.32% |
| Jun 2026 | 2.7× | 94.80% |
| Mar 2026 | 1.4× | 166.04% |
| Dec 2025 | 0.5× | (36.58%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRVE Braveheart Bio, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 0.9× |
| NVAX Novavax, Inc. | 3.3× |
| NTLA Intellia Therapeutics, Inc. compare | 20.9× |
| GENB Generate Biomedicines, Inc. compare | 37.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | 136× |
| ABSI Absci Corporation compare | 896× |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)